Beta blockers and calcium channel blockers are highlighted as effective, safe, metabolically neutral, and nephroprotective options for hypertension management.
Supports beta blockers and CCBs across comorbid hypertension; leaves open confirmation by randomized trials.
Although the response to antihypertensive therapy is individual, almost all antihypertensives reduce arterial pressure by 10-15%. From the analysis of the effectiveness of antihypertensives, both in monotherapy and comedication in patients with multiple comorbidities, through clinical studies and real-world data, it is concluded that beta blockers and calcium channel blockers have been proven to be effective and safe in all groups of patients. This comprehensive efficacy, with the optimal profile of side effects, results from proven efficacy in primary and secondary prevention of adverse cardiovascular events, impact on the sympathetic nervous system with nephroprotection, and metabolic neutrality.
No takes yet. Share an insight, caveat, or question.
Pandrc et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: